This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Charles River (CRL) Banks on RMS Growth Amid Competition
by Zacks Equity Research
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Here's Why You Should Retain Edward Lifesciences (EW) for Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.
Scoop up These 4 GARP Stocks to Receive Handsome Returns
by Zacks Equity Research
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. CSL, RMD, BAH and BAP are some stocks that hold promise.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
by Zacks Equity Research
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Reasons to Include Alcon (ALC) in Your Portfolio Right Now
by Zacks Equity Research
New product launches and strong solvency bode well for Alcon (ALC).
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by strategic alliances and new product launches.
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
by Zacks Equity Research
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Globus Medical (GMED) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
CVS Health (CVS) Expands Food and Beverage Line With New Launch
by Zacks Equity Research
CVS Health's (CVS) Well Market brand offers a blend of mouthwatering flavors and nutritious options, expertly crafted and taste-tested by food enthusiasts.
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
by Zacks Equity Research
Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
Here's Why You Should Buy Haemonetics (HAE) Stock Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.
Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
Wall Street Analysts See ResMed (RMD) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in ResMed (RMD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
Boston Scientific (BSX) mCRM System Study Outcome Favorable
by Zacks Equity Research
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Maravai (MRVI) Advances in RNA Research With New Collaboration
by Zacks Equity Research
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
What Makes ResMed (RMD) a New Strong Buy Stock
by Zacks Equity Research
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Align Technology (ALGN) Gains From Innovation, Global Expansion
by Zacks Equity Research
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
by Zacks Equity Research
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.